Navigation Links
Wyeth Announces Increase in Common Stock Dividend
Date:9/25/2008

MADISON, N.J., Sept. 25 /PRNewswire-FirstCall/ -- At a meeting of its Board of Directors, held today, Wyeth (NYSE: WYE) declared an increase in its common stock dividend.

A dividend of thirty cents ($0.30) per share on the outstanding shares of common stock was declared payable on December 1, 2008 to stockholders of record at the close of business on November 13, 2008. This quarterly rate represents a 7.1 percent increase per share from the previous quarter ($0.28).

The dividend increase is a result of Wyeth's positive cash position, strong operating cash flow, receding diet drug litigation payments, and management's confidence in both the short- and long-term growth prospects for the Company. Wyeth's goal is to maintain financial flexibility to allow for future growth opportunities while also providing value to its shareholders.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
2. Wyeth Sets Webcast And Conference Call for 2008 Third Quarter Earnings
3. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
4. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
5. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
6. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
7. Wyeth Announces Bernard Poussot Assumes Chairman of the Board Position
8. Wyeth Declares Common and Preferred Stock Dividends
9. Wyeth Pharmaceuticals Announces Organizational Change
10. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
11. Wyeth to Present at the 2008 Citi Investment Research Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... Two champions of science, technology, engineering, ... an annual competition for middle and high school students ... STEM study. The competition presents students with real-world problems ... Aptitude, Mathematics, and Sciences is a program administered ...
(Date:1/15/2014)... Arizona (PRWEB) January 15, 2014 2013 ... for Scottsdale’s Brain State Technologies®. They saw continued independent ... Medical Center who were awarded a $1 million grant ... published in “Brain and Behavior” a peer reviewed journal, ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Commercialization of the Revolutionary ... Accuri C6 Flow Cytometer(R) System--, ... a life,sciences company developing revolutionary bench-top flow cytometer systems,today ... financing led by,Fidelity Biosciences and Flagship Ventures. Current investors ...
... 8 Concentric Pharma Advertising, Inc., a,five-year-old ... growing in the,field, has been selected by ... a developmental once-daily,medication for the treatment of ... include a broad range of activities,including branding, ...
... 7 American Oriental,Bioengineering, Inc. (NYSE: AOB ... market conditions and other factors, $85 million aggregate,principal ... qualified,institutional buyers in a private placement exempt from ... as amended (the "Securities,Act")., AOB currently expects ...
Cached Biology Technology:Accuri Cytometers Completes $13 Million Series C Financing 2Accuri Cytometers Completes $13 Million Series C Financing 3Accuri Cytometers Completes $13 Million Series C Financing 4Concentric Wins Full-Service Professional Assignment From Biopharm Innovator Neuromed 2American Oriental Bioengineering Proposes Offering of $85 Million of Convertible Notes 2American Oriental Bioengineering Proposes Offering of $85 Million of Convertible Notes 3
(Date:4/23/2014)... The trope that the likelihood of an accurate group ... not hold up when a collective faces a variety ... nature. Instead, Princeton University researchers report that smaller groups ... assemblies may become excessively focused on only certain pieces ... to what is known about collective intelligence, or the ...
(Date:4/23/2014)... turning away from using triclosan as an antimicrobial ingredient ... And now scientists are reporting new evidence that appears ... ACS journal Chemical Research in Toxicology , found ... octylphenol, promoted the growth of human breast cancer cells ... , Kyung-Chul Choi and colleagues note that hormonal imbalances ...
(Date:4/23/2014)... disease is the first cause of dementia and affects ... cure has yet been found. One of the reasons ... cellular mechanisms which cause alterations in nerve transmissions and ... the disease., Researchers from the Institute of Neuroscience at ... mechanism involved in memory consolidation and were able to ...
Breaking Biology News(10 mins):Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2Loss of memory in Alzheimer's mice models reversed through gene therapy 2
... This press release is available in French ... and men contribute equally to the lineage of contemporary populations? ... polygamy or monogamy? To answer these questions, Dr. Damian Labuda, ... a professor at the Department of Pediatrics of the Universit ...
... professor of chemistry at New Jersey Institute of ... patent today for a novel composition of matter. ... (US Patent Number 7,670,684) discloses a new self-contained ... comprised of organic scaffolds with metal centers, which ...
... worldwide. It is the most common form of age-related dementia, ... no cure, and the available drugs only help to relieve ... characteristic changes in the brains of Alzheimer,s patients is the ... curing or at least slowing the disease lies in developing ...
Cached Biology News:Modern man found to be generally monogamous, moderately polygamous 2NJIT researcher awarded patent for hydrophobic, corrosion-resistant coating 2The sea squirt offers hope for Alzheimer's sufferers 2
Monoclonal Anti-Gα o purified immunoglobulin buffered aqueous solution Solution in phosphate buffered saline pH 7.4, containing 0.08% sodium azide. partially purified bovine brain Gα O ...
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
... cis- 9-Octadecenoyl-N-hydroxylamide Oleoyl-N-hydroxylamide White solid. ... A potent inhibitor of MMP-2 that acts ... = 1.7 μM). Purity: ≥98% by ... Unstable in solution, reconstitute just prior to ...
MAb to Vasopressin Preservative: NaN3...
Biology Products: